---
figid: PMC5199628__nihms836947f1
figtitle: Principles of Kinase Inhibitor Therapy for Solid Tumors
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC5199628
filename: nihms836947f1.jpg
figlink: /pmc/articles/PMC5199628/figure/F1/
number: F1
caption: Depiction of dysregulated oncogenic receptor tyrosine kinases (RTKs) and
  intracellular downstream mediators (green boxes). RTKs transduce signals from the
  binding of extracellular ligands and growth factors resulting in activation of downstream
  PI3K, JAK/STAT, PLC/PKC, and MAPK pathway mediators, causing nuclear translocation
  of transcription factor proteins, which regulate gene expression and the balance
  of proliferative and death signals within the cell. Molecular targets and their
  inhibitors are indicated (red boxes). Note that crizotinib and cabozantanib also
  target MET.
papertitle: Principles of Kinase Inhibitor Therapy for Solid Tumors.
reftext: Noah A. Cohen, et al. Ann Surg. ;265(2):311-319.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8765253
figid_alias: PMC5199628__F1
figtype: Figure
redirect_from: /figures/PMC5199628__F1
ndex: fecea9d7-df17-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5199628__nihms836947f1.html
  '@type': Dataset
  description: Depiction of dysregulated oncogenic receptor tyrosine kinases (RTKs)
    and intracellular downstream mediators (green boxes). RTKs transduce signals from
    the binding of extracellular ligands and growth factors resulting in activation
    of downstream PI3K, JAK/STAT, PLC/PKC, and MAPK pathway mediators, causing nuclear
    translocation of transcription factor proteins, which regulate gene expression
    and the balance of proliferative and death signals within the cell. Molecular
    targets and their inhibitors are indicated (red boxes). Note that crizotinib and
    cabozantanib also target MET.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - blo
  - Egfr
  - Alk
  - Ret
  - reticulated
  - reti
  - rets
  - ras
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Raf
  - Akt
  - Dsor1
  - Mtk
  - Mtor
  - Tor
  - Stat92E
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - Erk7
  - rl
  - MKP-4
  - p38b
  - KIT
  - EGFR
  - ALK
  - RET
  - ERBB2
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MAP2K3
  - MAP2K4
  - MAP2K5
  - MAP2K6
  - PLCB1
  - MTOR
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - EPHB2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - Temsirolimus
  - Vandetanib
  - Pazopanib
  - Regorafenib
  - Trametinib
  - Dabrafenib
  - Cobimetinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
